The feasibility of this approach has been demonstrated by studies using neutralizing antibodies against Noggin or Gremlin in the contexts of pulmonary arterial hypertension (PAH) and spinal cord injury [72–74]. The gene discussed is GREM1; the disease is pulmonary arterial hypertension.